Benchmarking the Global Stem Cell Science Base

An objective and evidence based anlaysis

Better Evidence - Smarter Business

• Biolauncher extends the principals of bioinfirmatics to business

development

• Integrating extensive and diverse sources of commercial life science

information to make informed business decisions

• Proprietary Information System called ShowcaseBio

• 350 publically available data feeds

• Advanced text analytics

• Visualisation

• Brings together patent, publication, company, news and more

• An extensive range of business applications

• This case study illustrates how the system enables open innovation and evidenced

based partnering strategies

Automated Semantic

Data Integration Processes

Semantic Database

News

& Deals

Company

Websites

Events &

Conferences

Directories &

Listings

Scientific

Literature

Patents &

Inventions

Market / Industry

Analysis

Targeted

Lead Generation

Sales Trip

Planner

Supply Chain

Management

Purchasing &

Partnering

Open

Innovation

Drugs, Devices,

Products & Services

ShowcaseBio System

Why Benchmark Cambridge, UK?

• Approached by regional inward investment agency – East of England

International

• Responsible for promoting Cambridge, UK as a destination for global life science

businesses

• Prioritising Stem cell science and regenerative medicine

• Wanted to understand “How good is Cambridge, UK?”

• Challenge of that question is you need to be able to answer “How good

is every other city in the world and where does Cambridge, UK rank?”

• Other centres are investing to attract stem cell business

Benchmarking Stem Cell Science

• Aim: To quantify Cambridge, UK stem cell research leadership

position

• Employ objective methodology that examines academic output

• Analysis performed using ShowcaseBio

• Considered peer review publications (academic output) recorded in

PubMed

• with MeSH heading of „Stem Cells‟

• Papers published between 2000 and 2009

• Divided into annual datasets

• Attributed and mapped total publications per city based upon first

author address

Total Number of Stem Cell Papers 2009

Total Publications Shows Capacity

• Each publication is not equivalent – some greatly advance the

understanding of the field, others are additive

• Biolauncher can not read each paper, nor are we qualified to make

judgements about each publications merits

• Employ Impact factors to rank publications by impact

• Used EigenFactor Article Influence™

• Article Influence score is a measure of the average influence of each of its

articles over the first five years after publication

• More information at www.eigenfactor.org

• Comparable to Thomson Scientific's widely-used Impact Factor

• Map the total impact factor by city to reveal total competence at each

location

Total Impact Factor – Competence

Total Impact Factor

• Total Impact Factor is a measure of capacity and competence at each

location.

• It does not reveal academic leadership, because

• Relatively few leaders in any subject

• Leadership is identified by the

• The prestige/impact of the journal that publishes papers

• Frequency that the publication is cited by peers

• Leaders have a higher average impact score than their peers

• Biolauncher calculated and mapped the average impact factor for the

top 15 cities for each year 2000-2009

Avg. Impact Factor - Leadership

0

1

2

3

4

5

6

7

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009

Avera

ge I

mp

act

Facto

rTop 15 Stem Cell Centres

Ann Arbor, US

Baltimore, US

Bethesda, US

Boston, US

Cambridge, US

Cambridge, GB

Houston, US

London, GB

Los Angeles, US

New York, US

Paris, FR

Philadelphia, US

San Francisco, US

Stanford, US

Tokyo, JP

Conclusions

• Cambridge scientists are publishing influential research

• Cambridge and London leading location for research in Europe,

combining leadership and capacity

• Cambridge, UK as an important open innovation destination for

companies seeking to access stem cell innovation

• Methodology provides an objective approach to assessing academic

leadership in any life science domain

Limitations of the Analysis

• Affiliation information is usually only associated with the first author of

a paper. For collaborative papers with multiple authors at different

insitutions this may mean that some attributions are missed.

• All average impact factors are fundamentally based on citation

metrics within a large but finite pool of publications, the majority of

which are English language journals. This inevitably discriminates

against papers that are written in languages other than English.

• Not all addresses provided in PubMed will geocode correctly. Badly

formed or incomplete addresses may be excluded from this analysis.

• BioLauncher chose not to aggregate closely related place names, e.g.

Stanford and Palo Alto ; Cambridge and Boston, US or Cambridge

and London, UK.

Commercial Strategy Applications

• Planning market entry strategy, licensing partner or investor exit

• Review clinical trials to understand product development potential

• Choosing an overseas location – consider direct flight destinations

from the nearest airport - can you reach customers easily?

• Best results arise from being able to consider a wide range of

information

• Expect to review results to effectively prioritise opportunity

Service or

Technology

Offered/Wanted

Characterise

Target

Businesses

Refine Query Review

ResultsAct!

Connections to European Biologics Market

Stansted

Airport

Grey discs show a 50

mile radius around

airports served by

London Stansted –

30 minutes from

Cambridge, UK

Case Study: Finding Licensing Deals

Service or

Technology

Offered/Wanted

Characterise

Target Businesses

Refine Query

Review

Results

Act!

Marketing division seeking high value diagnostic imaging products to launch in Far East

Modality specific, CE marked/FDA approved with diagnostic application to Liver, Abdomen,

Breast, Point of Care, Emergency Room without access to Far Eastern Market

Expanded query terms to look for relevant terms,

using text analytics and vocabulary tools in ShowcaseBio

Identified a due diligence set of 230 companies for review,

grouped by diagnostic indication(s) and stage of clinical approval

Prioritised 8 companies as a shortlist for consideration.

527,075 pages

over 41,500

companies

Find out more...

• Visit our website biolauncher.com

• Examine our track record http://biolauncher.com/track-record/

• Meet the team http://biolauncher.com/about/

• And contact us, our contact information is here

http://biolauncher.com/contact/ and it costs nothing to talk!